VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | APR-246 combination treatments in TP53-mutant R/R NHLs

Meghan Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses an upcoming Phase 1 study (NCT04419389) aiming to evaluate the efficacy and safety of APR-246 in combination with ibrutinib or a venetoclax-based therapy in patients with TP53-mutant relapsed/refractory (R/R) non-Hodgkin lymphomas (NHLs), including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Enrollment for this trial is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Curio Science

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter